Our company has continued on its strong growth trajectory in the first nine months of 2024. Total Revenue and Core EPS were up 21% and 27% respectively in the third quarter, reflecting the increasing demand for our medicines across Oncology, BioPharmaceuticals and Rare Disease and supporting an upgrade to our full year 2024 guidance.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
Latest presentations
9M and Q3 2024 results
We have
199
projects in our pipeline
Corporate Press Release
